Mylan's Aflibercept Biosimilar Gets Green Light For Trials In India
Executive Summary
Mylan’s proposal to progress studies for its aflibercept biosimilar has been endorsed by an expert panel in India, which expects availability of such biosimilars to expand access to anti-VEGF therapies.
You may also be interested in...
Strides Plans Re-Entry On Injectables
Indian firm Strides to invest up to $40m in acquired Stelis for re-entry into generic injectables and multiple biosimilar APIs as it looks to build its business.
Strides Plans Injectables Re-entry As Mylan Non-Compete Nears End
Indian firm Strides to invest up to $40m in acquired Stelis for re-entry into generic injectables and multiple biosimilar APIs as it looks to build its business.
Korea IND Filing Moves Alteogen's Eylea Biosimilar Forward
South Korean biotech Alteogen is progressing the development of its Eylea biosimilar both at home and abroad, with the hope of becoming a global first mover with its version in wet AMD, backed by formulation and manufacturing patents.